Arovella Therapeutics

AU: ALA

Market CapAU$16.8m

Last Close AU$0.04

Arovella Therapeutics is a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system.

More Arovella Therapeutics content >

Investment summary

Arovella Therapeutics (ALA) is a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system. Its most advanced product is ZolpiMist, an oro-mucosal spray version of Ambien for the treatment of insomnia that is partnered in certain regions with Teva and STADA Pharmaceuticals Australia. ALA recently in-licensed an invariant natural killer T (iNKT) cell therapy platform that can be used in conjunction with chimeric antigen receptors to target blood cancers. There are a number of potential benefits of CAR-iNKT, including the prospect of being an allogeneic ‘off-the-shelf’ therapy, significantly simplifying the manufacture of the therapy and its delivery to patients. The therapy is currently preclinical and could be transformative for the company.

Y/E Jun
Revenue (A$m)
EBITDA (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2019A 1.2 (1.9) (2.4) (1.54) N/A N/A
2020A 0.5 (4.1) (4.7) (2.81) N/A N/A
2021E 0.5 (3.6) (4.3) (1.29) N/A N/A
2022E 1.0 (5.9) (6.6) (1.37) N/A N/A
Industry outlook

ALA is targeting very large markets including insomnia (through ZolpiMist) and various cancers (through the CAR-iNKT programme as well as anagrelide).

Last updated on 06/12/2021
Content on Arovella Therapeutics
SUDA Pharmaceuticals – Half-year update
Healthcare | Update | 11 March 2021
pexels-photo-4021779
Suda Pharmaceuticals – A TGA approval and a capital raise
Healthcare | Update | 3 September 2020
pexels-photo-4021779
View more
Register to receive research on Arovella Therapeutics as it is published
Share price graph
Balance sheet
Forecast net cash (A$m) 6.7
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (14.6) (36.4) (7.9)
Relative* (12.7) (34.5) (16.3)
52-week high/low A$0.1/A$0.0
*% relative to local index
Key management
Michael Baker CEO and Managing Director